Symtomax Portugal, a medical cannabis operator, has announced that it has been granted approval to commence cultivation from INFARMED, the Portuguese regulatory authority for the pharmaceutical industry in Portugal. The approval allows Symtomax to cultivate, import and export GACP-quality dried flower, produced from their facility in Portugal.
Symtomax was established in 2017 with a commitment to advancing alternative and effective products to improve the health and well-being of people. The Symtomax team of professionals have decades of combined experience in cannabis cultivation, adhering to strict procedural and environmental protocols to maximise purity, quality and consistency.
The company has built partnerships that will improve consumers’ access to the best products around the world as well as invested in industry-leading research and development. This strategy allows Symtomax to use leading technology to develop high-quality and technologically advanced cannabis products that can be sold around the world.
Symtomax’s site of 105 hectares, of which 95 hectares has been approved for the cultivation of medical flower. The company has a large selection of sativa dominant, indica dominant, hybrids and CBD strains. The license will allow Symtomax to develop into a vertically-integrated cannabis business, cultivating from both indoor and outdoor facilities, with future  plans for R&D, to processing, packaging and distribution of medicinal cannabis oil and other cannabinoid-based products.
The company has established strategic partnerships with leading industry companies dedicated to the promotion and development of cannabis for medicinal purposes, in helping to treat a number of different conditions including cancer, arthritis, Alzheimer’s, depression, dementia, anxiety and even in its use for treating eating disorders such as anorexia.
This INFARMED approval is a huge milestone for the company and firmly positions Symtomax, as a leading supplier of cannabis flower to the medical industry across Europe and further afield.
For more information, visit: www.symtomax.com
